Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ALPG | P10696 | 2/20 | 0.55 |
| ▸ | ALPL | P05186 | 1/20 | 0.55 |
| ▸ | ALPI | P09923 | 1/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | GALK1 | P51570 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29985579 | 1.00 | KDM4E (0.60) | KDM4EALDH1A1MAPK1HSD17B10POLB | |
| SCHEMBL1004449 | 0.88 | KDM4E (0.69) | KDM4EALDH1A1POLBIGF1RMEN1 | |
| SCHEMBL3576792 | 0.84 | ALDH1A1 (0.67) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1515768 | 0.81 | KDM4E (0.61) | KDM4EALDH1A1POLBMEN1KMT2A | |
| SCHEMBL403220 | 0.81 | KDM4E (0.61) | KDM4EALDH1A1POLBMEN1KMT2A | |
| SCHEMBL8585914 | 0.81 | KDM4E (0.66) | KDM4EALDH1A1POLBMEN1KMT2A | |
| SCHEMBL1527149 | 0.81 | KDM4E (0.61) | KDM4EALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL15553080 | 0.81 | KDM4E (0.75) | KDM4EALDH1A1HSD17B10POLBMEN1 | |
| SCHEMBL29361178 | 0.81 | GAA (0.64) | KDM4EALDH1A1MAPK1POLBMEN1 | |
| SCHEMBL565133 | 0.81 | GAA (0.64) | KDM4EALDH1A1MAPK1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0488860-B1 | Method for the production of polyalkoxylated aromatic compounds | RHONE POULENC CHIMIE (FR) | 1995-10-11 | — | — | EP | claimed |
| EP-0423010-B1 | METHOD FOR THE PRODUCTION OF ALKOXYBENZALDEHYDES | RHONE-POULENC CHIMIE (FR) | 1993-09-29 | — | — | EP | claimed |
| US-11993562-B2 | Methods for isolation and purification of cannabidiol (CBD) and terpenes from hemp | RJ LEE GROUP, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-20220324780-A1 | METHODS FOR ISOLATION AND PURIFICATION OF CANNABIDIOL (CBD) AND TERPENES FROM HEMP | RJ LEE GROUP, INC. | 2022-10-13 | — | — | US | disclosed |
| US-9283229-B2 | Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150224107-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2015-08-13 | — | — | US | disclosed |
| US-9067893-B2 | Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140235640-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8741915-B2 | Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8436197-B2 | Palladium complexes and polymerization and coupling processes thereof | WEST CHESTER UNIVERSITY OF PENNSYLVANIA OF THE STATE SYSTEM OF HIGHER EDUCATION (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120208817-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC (US) | 2012-08-16 | — | — | US | disclosed |
| WO-2004009596-A2 | PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
| US-6268391-B1 | Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases | GLAXO WELLCOME INC. | 2001-07-31 | — | — | US | disclosed |
| EP-1003721-A1 | BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES | GLAXO GROUP LIMITED (GB) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999010325-A1 | BENZYLIDENE-1,3-DIHYDRO-INDOL-2-ONE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS, PARTICULARLY OF RAF KINASES | GLAXO GROUP LIMITED (GB) | 1999-03-04 | — | — | WO | disclosed |
| EP-0212095-B1 | THERMOSETTABLE COMPOUNDS PREPARED FROM MONOHYDROXY AROMATIC ALDEHYDES AND METHYLATED PYRIDINES OR PYRAZINES | THE DOW CHEMICAL COMPANY (US) | 1989-09-06 | — | — | EP | disclosed |
| EP-0212095-A1 | Thermosettable compounds prepared from monohydroxy aromatic aldehydes and methylated pyridines or pyrazines | THE DOW CHEMICAL COMPANY (US) | 1987-03-04 | — | — | EP | disclosed |
| US-4600767-A | Thermostable hydroxystyrylaza compounds | THE DOW CHEMICAL COMPANY (US) | 1986-07-15 | — | — | US | disclosed |
| US-3993761-A | 2,4-DIAMINO-5-(3-ALKOXY-4,5-METHYLENEDIOXYBENZYL)-PYRIMIDINES | HOFFMANN-LA ROCHE INC. (US) | 1976-11-23 | — | — | US | disclosed |
| US-3962435-A | ANTIBACTERIAL | HOFFMANN-LA ROCHE INC. (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235640-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | QDPR, GSR, CBR1 | KDM4E 3194/4885ALDH1A1 207/4885MAPK1 3801/4885 |
| US-20220324780-A1 | METHODS FOR ISOLATION AND PURIFICATION OF CANNABIDIOL (CBD) AND TERPENES FROM HEMP | CNR2, CNR1, CYP8B1 | KDM4E 2463/4885ALDH1A1 3151/4885MAPK1 4181/4885 |
| US-20120208817-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | QDPR, GSR, CBR1 | KDM4E 3194/4885ALDH1A1 207/4885MAPK1 3801/4885 |
| US-11993562-B2 | Methods for isolation and purification of cannabidiol (CBD) and terpenes from hemp | CNR2, CNR1, CYP8B1 | KDM4E 2463/4885ALDH1A1 3151/4885MAPK1 4181/4885 |
| US-20150224107-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | QDPR, GSR, CBR1 | KDM4E 3194/4885ALDH1A1 207/4885MAPK1 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.